Featuring a slide presentation and related discussion from Dr Lindsey Roeker, including the following topics:

• Recent clinical updates with standard regimens for chronic lymphocytic leukemia (CLL) (0:00)
• Utility of minimal residual disease-guided treatment intensification after ibrutinib with venetoclax  (7:03)
• Major long-term findings from the GLOW study of ibrutinib with venetoclax (10:35)
• Principal findings from the AMPLIFY study of acalabrutinib with venetoclax with or without obinutuzumab (12:28)
• Findings with combined acalabrutinib, venetoclax and obinutuzumab for patients with previously untreated high-risk disease  (15:52)
• Early clinical findings with sonrotoclax and zanubrutinib as front-line treatment for CLL (18:12)
• Principal findings from the BRUIN CLL-321 trial of pirtobrutinib for patients who previously received a covalent Bruton tyrosine kinase (BTK) inhibitor  (19:38)
• Emerging evidence with pirtobrutinib, venetoclax and obinutuzumab as front-line treatment  (22:15)
• Novel strategy combining lisocabtagene maraleucel with ibrutinib for relapsed/refractory (R/R) CLL (24:13)
• Available data with epcoritamab monotherapy for R/R CLL  (26:58)
• The emerging pharmacologic class of BTK degraders  (29:04)

CME information and select publications